Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Similar articles for PubMed (Select 9892208)


Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Cai W, Kerner ZJ, Hong H, Sun J.

Biochem Insights. 2008 Jul 22;2008:15-21.


Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

Van Hauwermeiren F, Armaka M, Karagianni N, Kranidioti K, Vandenbroucke RE, Loges S, Van Roy M, Staelens J, Puimège L, Palagani A, Berghe WV, Victoratos P, Carmeliet P, Libert C, Kollias G.

J Clin Invest. 2013 Jun;123(6):2590-603. doi: 10.1172/JCI65624. Epub 2013 May 15.


TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model.

de Lima VC, de Carvalho AF, Morato-Marques M, Hashimoto VL, Spilborghs GM, Marques SM, Landman G, Torres C, Braga Ribeiro K, Brentani H, Reis LF, Dias AA.

Cytokine. 2013 May;62(2):217-25. doi: 10.1016/j.cyto.2013.02.022. Epub 2013 Mar 25.


Won't you come on in? How to favor lymphocyte infiltration in tumors.

Bellone M, Calcinotto A, Corti A.

Oncoimmunology. 2012 Sep 1;1(6):986-988.


Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.

Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A.

Cancer Res. 2011 Sep 1;71(17):5881-90. doi: 10.1158/0008-5472.CAN-11-1273. Epub 2011 Jul 28.


TNF: a tumor-suppressing factor or a tumor-promoting factor?

Balkwill F, Joffroy C.

Future Oncol. 2010 Dec;6(12):1833-6. doi: 10.2217/fon.10.155.


Lung self-assembly is modulated by tissue surface tensions.

Schwarz MA, Zheng H, Legan S, Foty RA.

Am J Respir Cell Mol Biol. 2011 May;44(5):682-91. doi: 10.1165/rcmb.2009-0309OC. Epub 2010 Jul 8.


Deciphering the immune function and regulation by a TLR of the cytokine EMAPII in the lesioned central nervous system using a leech model.

Schikorski D, Cuvillier-Hot V, Boidin-Wichlacz C, Slomianny C, Salzet M, Tasiemski A.

J Immunol. 2009 Dec 1;183(11):7119-28. doi: 10.4049/jimmunol.0900538. Epub 2009 Nov 16.


Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.

Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK.

Exp Cell Res. 2009 Jul 1;315(11):1850-9. doi: 10.1016/j.yexcr.2009.03.021. Epub 2009 Apr 10.


Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK.

PLoS One. 2009;4(3):e4972. doi: 10.1371/journal.pone.0004972. Epub 2009 Mar 30.


Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.

Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK.

Cancer. 2009 Jan 1;115(1):128-39. doi: 10.1002/cncr.24001.


Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E, Efimova E, Darga T, Khodarev NN, King CR, Posner MC, Hellman S, Kufe DW, Weichselbaum RR.

Cancer Gene Ther. 2009 Apr;16(4):373-81. doi: 10.1038/cgt.2008.86. Epub 2008 Oct 31.


Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.

Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, Corti A.

Cancer Res. 2008 Feb 15;68(4):1154-61. doi: 10.1158/0008-5472.CAN-07-2085.


Tumor necrosis factor-alpha promotes malignant pleural effusion.

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I.

Cancer Res. 2007 Oct 15;67(20):9825-34.


Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.

Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer Ga, van Tiel ST, Eggermont AM, Ten Hagen TL.

Cancer Res. 2007 Oct 1;67(19):9455-62.


Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters.

Koszałka P, Szmit E, Myśliwski A, Bigda J.

Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):267-79. Epub 2007 Jul 23.


Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP.

J Urol. 2007 May;177(5):1900-6.


Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor.

Farma JM, Puhlmann M, Soriano PA, Cox D, Paciotti GF, Tamarkin L, Alexander HR.

Int J Cancer. 2007 Jun 1;120(11):2474-80.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk